Protext Mobility, Inc. (OTC: TXTM) Announces Strategic TruLeaf Partnership & Next-Level Innovation

Rhea-AI Summary

Protext Mobility (OTC: TXTM) announced a strategic Letter of Intent with TruLeaf on November 17, 2025, aiming to accelerate technology adoption, market expansion, and new financial applications using CBD-based assets.

TruLeaf will provide product samples, initial inventory shipments, infrastructure and operational support. The partnership claims TruLeaf nanotechnology will increase bioavailability of TXTM’s kettle technology, enable THC-free CBD FECO aligned with Farm Bill compliance, and create an API that the company describes as a real-world asset (RWA) recognized under IFRS/GAAP. The release also frames potential future uses, including a stablecoin, staking, and liquidity applications for shareholders.

Positive

• LOI with TruLeaf announced on Nov 17, 2025
• TruLeaf to provide product samples, initial inventory, infrastructure
• Claims of increased bioavailability via TruLeaf nanotechnology
• THC-free CBD FECO claimed to align with Farm Bill compliance

Negative

• Agreement is a Letter of Intent, not a finalized binding contract
• No financial figures, timelines, or binding commercial terms disclosed
• RWA recognition under IFRS/GAAP and stablecoin plans are described as potential, not guaranteed

FORT LAUDERDALE, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM) (“Protext” or the “Company”) is proud to announce a strategic Letter of Intent (LOI) with TruLeaf, marking a pivotal moment in the company’s growth and mission. This partnership not only accelerates technology adoption and market expansion but also opens the door to innovative financial applications leveraging CBD-based assets.

Highlights:

• TruLeaf provides strategic support, including product samples, initial inventory shipments, infrastructure support, and operational resources.
• Perfect synergy: TruLeaf’s nanotechnology enhances TXTM’s kettle technology, significantly increasing bioavailability. Products are cheaper, faster-acting, and more effective, benefiting patients worldwide.
• TruLeaf’s natural CBD FECO without THC, combined with Farm Bill compliance, provides a regulatory and competitive advantage.
• The resulting API (active pharmaceutical ingredient) and mg quantities of CBD can be treated as real-world assets (RWA) on the company’s balance sheet, recognized under IFRS/GAAP as income/gain, strengthening net profit without cash outflow.
• These assets could potentially support the creation of a stablecoin, enabling future staking, investment, or liquidity applications — a true financial innovation benefiting all shareholders.
• This partnership is aligned with TXTM Tribe Mission: raising all boats by improving patient outcomes, advancing global healing, and creating shareholder value.

Strategic Rationale

1. Technological Synergy & Bioavailability
   • TruLeaf’s nanotechnology complements TXTM’s kettle technology.
   • Dramatically increases bioavailability, improving effectiveness and speed of action for patients.
   • Reduces production costs, enhancing shareholder value.
   • Supports the mission of global healing and patient wellbeing.
2. Regulatory & Competitive Advantage
   • THC-free CBD FECO aligns with Farm Bill compliance.
   • Provides a clear market differentiation and competitive edge.
3. Financial Strengthening & Asset Potential
   • CBD API is a real-world asset (RWA) recognized under IFRS/GAAP as income/gain.
   • Strengthens balance sheet, net profit, and potential share price.
   • RWA could support innovative stablecoin creation or staking mechanisms, creating new financial opportunities for the company and shareholders.
4. Market Validation & Mission Impact
   • TruLeaf’s support is a vote of confidence from a successful, established partner.
   • Accelerates growth, operational scaling, and market entry.
   • Delivers meaningful impact for patients and the TXTM Tribe Mission: “raising all boats.”

Dylon Du Plooy, CEO, mentioned:

“This is a landmark moment for TXTM. TruLeaf’s nanotechnology enhances our kettle technology, dramatically increasing bioavailability, making our products more effective, faster, and more affordable for patients. The resulting API is a real-world asset on our balance sheet, recognized as income/gain, and has the potential to support stablecoin creation for staking or investment — a transformative financial innovation. Combined with THC-free CBD FECO and Farm Bill compliance, we now have a regulatory and competitive advantage. This partnership accelerates growth, strengthens our market position, and aligns perfectly with the TXTM Tribe Mission: raising all boats, for shareholders, patients, and global healing.”

About Protext Mobility, Inc. (OTC: TXTM)

Protext Mobility is focused on the research, testing, and development of highly bioavailable, nanotechnology-based botanical formulations for nutraceutical and pharmaceutical applications. Through proprietary live plant extraction technologies, the company aims to advance plant-based therapeutics that address wellness and health needs globally.

Investor & Media Contact:
Dylon Du Plooy – dylon@rsammd.co.za
Dr. J – exportintl@aol.com

Follow Us:
X (Twitter): https://x.com/ProtextP

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Actual results may differ materially due to market conditions, foreign exchange fluctuations, operational execution, regulatory requirements, and other risks detailed in the Company’s filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements.

FAQ

What did Protext Mobility (OTC: TXTM) announce on November 17, 2025?

TXTM announced a strategic Letter of Intent with TruLeaf to provide product samples, inventory, infrastructure support, and technology collaboration.

How does the TruLeaf partnership affect TXTM product effectiveness?

The release says TruLeaf’s nanotechnology complements TXTM’s kettle technology to increase bioavailability, making products faster-acting and more effective.

Will the TruLeaf deal change TXTM’s financials or balance sheet?

The company states CBD API could be treated as a real-world asset (RWA) recognized under IFRS/GAAP, but no financial figures or binding valuations were disclosed.

Does the TruLeaf partnership include regulatory advantages for TXTM (OTC: TXTM)?

The announcement highlights THC-free CBD FECO and alignment with the Farm Bill as a regulatory and competitive advantage.

Is the stablecoin or staking plan from TXTM guaranteed after the LOI?

No; the press release describes stablecoin or staking as a potential future application supported by RWAs, not a confirmed or binding plan.

What immediate operational support will TruLeaf provide to TXTM?

TruLeaf will supply product samples, initial inventory shipments, infrastructure and operational resources per the announcement.